NLS Pharmaceutics AG (NLSPW)

Etorro trading 970x250

About NLS Pharmaceutics AG

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland. Address: Alter Postplatz 2, Stans, Switzerland, 6370

NLS Pharmaceutics AG News and around…

Latest news about NLS Pharmaceutics AG (NLSPW) common stock and company :

NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
30 Nov, 2021 Yahoo! Finance

STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces final results from a preclinical study for NLS-4 (Lauflumide), the Company's next-generation wake-promoting drug candidate.

NLS Pharmaceutics CEO Issues Letter to Shareholders
01 Nov, 2021 FinancialContent
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
14 Oct, 2021 Yahoo! Finance

STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces preclinical data for NLS-4 (Lauflumide), the Company's next-generation wake-promoting drug candidate, which has shown promise for the treatment of chronic fatigue associated with Long-

36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
04 Oct, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th \- 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Fall Harvest - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, October 5th, 2021, with company presentations beginning at 8:30 am Eastern Time.

NLS Pharmaceutics (NASDAQ:NLSP) Will Have To Spend Its Cash Wisely
30 Sep, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
30 Sep, 2021 Yahoo! Finance

STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to present a corporate overview and meet with investors at The Micro Cap Rodeo Fall Harvest Conference to be held

NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
28 Sep, 2021 Yahoo! Finance

STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has entered into a standby equity distribution agreement, or SEDA, with YA II PN, Ltd.

NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
24 Sep, 2021 FinancialContent
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled
14 Sep, 2021 FinancialContent
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
08 Sep, 2021 FinancialContent
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation
19 Aug, 2021 FinancialContent
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
05 Aug, 2021 Yahoo! Finance

STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021.

NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
19 Jul, 2021 FinancialContent
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy
15 Jul, 2021 FinancialContent
NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th
09 Jul, 2021 FinancialContent
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
08 Jul, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th \- 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.

NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering
02 Feb, 2021 Yahoo! Finance

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the closing of its initial public offering of 4,819,277 units at a price of $4.15 per unit. Each unit consisted of one common share and one warrant to purchase one common share (the "Warrants"). The common shares and Warrants were immediately separable from the units and were issued separately. The common shares and Warrants began trading on the Nasdaq Capital Market on January 29, 2021 under the symbols "NLSP" and "NLSPW," respectively. NLS received gross proceeds of approximately $20.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $4.15 per share. In addition, NLS granted the underwriters a 45-day option to purchase up to an additional 722,891 common shares and/or Warrants to purchase 722,891 common shares, of which Maxim exercised its option to purchase warrants to purchase up to 722,891 shares of common stock.

NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering
29 Jan, 2021 Yahoo! Finance

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the pricing of its initial public offering of 4,819,277 units at a price of $4.15 per unit. Each unit consists of one common share and one warrant to purchase one common share (the "Warrants"). The common shares and Warrants are immediately separable from the units and will be issued separately. The common shares and Warrants have been approved for listing on the Nasdaq Capital Market under the symbols "NLSP" and "NLSPW," respectively, and are expected to begin trading on January 29, 2021. NLS expects to receive gross proceeds of approximately $20.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants are exercisable immediately, expire five years from the date of issuance and will have an exercise price of $4.15 per share. The offering is expected to close on February 2, 2021, subject to customary closing conditions.

NLS Pharmaceutics AG (NLSPW) is a NASDAQ Common Stock listed in

970x250